Background: Standard inflammatory biomarkers, such as C-reactive protein (CRP) and ESR, frequently fail to capture the molecular complexity of the tumor microenvironment (TME) and the nuanced drives of systemic autoimmunity. This lack of granularity can lead to sub-optimal management of complex patients who may harbor "molecularly invisible" inflammation.

Objective: This pilot case series evaluates the clinical utility of a comprehensive 13-cytokine profile (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17A, IFN-γ, TNF-α, and IL-22) in mapping immune dysregulation and guiding personalized immunomodulatory interventions. Methods: We analyzed 15 patients (n=15) with diverse clinical backgrounds, including newly diagnosed and treated malignancies, chronic autoimmune disorders (MS, Crohn’s, Psoriatic Arthritis), and post-viral syndromes. Systemic cytokine levels were quantified using a bead-based multiplex immunoassay.

Results: Analysis of the 15 diverse cases revealed a complex immunological landscape characterized by "molecularly discordant" signatures. A dominant IL-6/IL-17A axis emerged as the primary driver of disease activity; peak values reached 58 pg/mL for IL-6 in acute oncology complications and 46 pg/mL for IL-17A in treatment-resistant autoimmunity. Crucially, these elevations often occurred despite unremarkable CRP/ESR levels, demonstrating that conventional metrics fail to capture high-velocity cytokine dysregulation. Notably, elevations in IL-1β (up to 20 pg/mL) and IL-8 (up to 15 pg/mL) were observed in cases of systemic flares and neuro-inflammation, respectively. Conversely, a critical Interleukin-10 (IL-10) deficiency (≤ 2 pg/mL) was identified in 85.7 % of symptomatic patients, highlighting a pervasive "Regulatory Gap". Specific cytokine clusters successfully mapped to clinical phenotypes, such as a Th2-driven IL-13 surge (up to 25 pg/mL) in tissue remodeling and IL-4 (8 pg/mL) in inflammatory pruritus.

Conclusion: Multi-cytokine profiling provides a critical "molecular compass" for clinicians, allowing for the identification of therapeutic gaps and the monitoring of immune homeostasis. This approach enables a transition from symptomatic management to precision immunomodulation, utilizing targeted agents to restore the regulatory balance.